Literature DB >> 29371378

Phenotypes of organ involvement in sarcoidosis.

Jonas Christian Schupp1, Sandra Freitag-Wolf2, Elena Bargagli3, Violeta Mihailović-Vučinić4, Paola Rottoli3, Aleksandar Grubanovic1, Annegret Müller1,5, Arne Jochens2, Lukas Tittmann6, Jasmin Schnerch1,7, Carmela Olivieri3, Annegret Fischer8, Dragana Jovanovic4, Snežana Filipovic4, Jelica Videnovic-Ivanovic4, Paul Bresser9, René Jonkers9, Kate O'Reilly10, Ling-Pei Ho11, Karoline I Gaede12,13, Peter Zabel12,13, Anna Dubaniewicz14, Ben Marshall10, Robert Kieszko15, Janusz Milanowski15, Andreas Günther16, Anette Weihrich17, Martin Petrek18,19, Vitezslav Kolek18,19, Michael P Keane20,21, Sarah O'Beirne20,21, Seamas Donnelly20,21, Sigridur Olina Haraldsdottir22, Kristin B Jorundsdottir22, Ulrich Costabel23, Francesco Bonella23, Benoît Wallaert24, Christian Grah25, Tatjana Peroš-Golubičić26, Mauritio Luisetti27, Zamir Kadija27, Stefan Pabst28, Christian Grohé29, János Strausz30, Martina Vašáková31,32, Martina Sterclova31,32, Ann Millar33, Jiří Homolka34, Alena Slováková34, Yvonne Kendrick11, Anjali Crawshaw11, Wim Wuyts35, Lisa Spencer36, Michael Pfeifer37, Dominique Valeyre38, Venerino Poletti39, Hubertus Wirtz40, Antje Prasse1,41, Stefan Schreiber8,42, Michael Krawczak2, Joachim Müller-Quernheim43.   

Abstract

Sarcoidosis is a highly variable, systemic granulomatous disease of hitherto unknown aetiology. The GenPhenReSa (Genotype-Phenotype Relationship in Sarcoidosis) project represents a European multicentre study to investigate the influence of genotype on disease phenotypes in sarcoidosis.The baseline phenotype module of GenPhenReSa comprised 2163 Caucasian patients with sarcoidosis who were phenotyped at 31 study centres according to a standardised protocol.From this module, we found that patients with acute onset were mainly female, young and of Scadding type I or II. Female patients showed a significantly higher frequency of eye and skin involvement, and complained more of fatigue. Based on multidimensional correspondence analysis and subsequent cluster analysis, patients could be clearly stratified into five distinct, yet undescribed, subgroups according to predominant organ involvement: 1) abdominal organ involvement, 2) ocular-cardiac-cutaneous-central nervous system disease involvement, 3) musculoskeletal-cutaneous involvement, 4) pulmonary and intrathoracic lymph node involvement, and 5) extrapulmonary involvement.These five new clinical phenotypes will be useful to recruit homogenous cohorts in future biomedical studies.
Copyright ©ERS 2018.

Entities:  

Mesh:

Year:  2018        PMID: 29371378     DOI: 10.1183/13993003.00991-2017

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  31 in total

1.  Highlights from the 2018 European Respiratory Society Congress presentations on interstitial lung diseases.

Authors:  Tiago M Alfaro; Margarida Afonso; Sebastiano Emanuele Torrisi
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

2.  Quality of Life of Couples Living with Sarcoidosis.

Authors:  Mareye Voortman; Celine M R Hendriks; Paul Lodder; Marjolein Drent; Jolanda De Vries
Journal:  Respiration       Date:  2019-08-22       Impact factor: 3.580

3.  Clinical, imaging and functional determinants of sarcoidosis phenotypes in a Greek population.

Authors:  Georgios Spyropoulos; Kalliopi Domvri; Katerina Manika; Evangelia Fouka; Theodoros Kontakiotis; Despoina Papakosta
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

4.  Income and Other Contributors to Poor Outcomes in U.S. Patients with Sarcoidosis.

Authors:  Logan J Harper; Alicia K Gerke; Xiao-Feng Wang; Manuel L Ribeiro Neto; Robert P Baughman; Kelli Beyer; Marjolein Drent; Marc A Judson; Lisa A Maier; Leslie Serchuck; Noopur Singh; Daniel A Culver
Journal:  Am J Respir Crit Care Med       Date:  2020-04-15       Impact factor: 21.405

5.  Sarcoidosis in the UK: insights from British Thoracic Society registry data.

Authors:  Muhunthan Thillai; William Chang; Nazia Chaudhuri; Ian Forrest; Ling-Pei Ho; Sarah Lines; Toby M Maher; Lisa G Spencer; Monica Spiteri; Robina Coker
Journal:  BMJ Open Respir Res       Date:  2019-02-18

6.  Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6.

Authors:  Laura Bergantini; Francesco Bianchi; Paolo Cameli; Maria Antonietta Mazzei; Annalisa Fui; Piersante Sestini; Paola Rottoli; Elena Bargagli
Journal:  Dis Markers       Date:  2019-03-03       Impact factor: 3.434

Review 7.  Host-microbe interactions in the pathogenesis and clinical course of sarcoidosis.

Authors:  Pleiades T Inaoka; Masato Shono; Mishio Kamada; J Luis Espinoza
Journal:  J Biomed Sci       Date:  2019-06-11       Impact factor: 8.410

8.  Clinical characterization and outcomes of 85 patients with neurosarcoidosis.

Authors:  Manuel Ramos-Casals; Roberto Pérez-Alvarez; Belchin Kostov; Ricardo Gómez-de-la-Torre; Carlos Feijoo-Massó; Joel Chara-Cervantes; Blanca Pinilla; Andrés González-García; José-Salvador Garcia-Morillo; Miguel López-Dupla; Begoña De-Escalante; Javier Rascón; Patricia Perez-Guerrero; Mariona Bonet; Gracia Cruz-Caparrós; Ana Alguacil; José-Luis Callejas; Eva Calvo; Cristina Soler; Angel Robles; Borja de Miguel-Campo; Pedro Oliva-Nacarino; Jorge Estela-Herrero; Lucio Pallarés; Pilar Brito-Zerón; Yolanda Blanco
Journal:  Sci Rep       Date:  2021-07-02       Impact factor: 4.379

9.  Psychometric properties of the German version of the Leicester Cough Questionnaire in sarcoidosis.

Authors:  Jonas Christian Schupp; Urs Alexander Fichtner; Björn Christian Frye; Katja Heyduck-Weides; Surinder S Birring; Wolfram Windisch; Carl-Peter Criée; Joachim Müller-Quernheim; Erik Farin
Journal:  PLoS One       Date:  2018-10-04       Impact factor: 3.240

10.  Clinical phenotyping in sarcoidosis management.

Authors:  Giuseppe Domenico Rana; Miriana d'Alessandro; Luigi Rizzi; Laura Bergantini; Paolo Cameli; Alfredo Vozza; Piersante Sestini; Patrizia Suppressa; Elena Bargagli
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2021-06-28       Impact factor: 0.670

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.